Drug Trial Radar · NCT03274492
A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma
Last checked: Nov 20, 2026Latest source record: May 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,000
Actual
Start
Nov 16, 2017
Primary completion
Apr 30, 2026
Study completion Apr 30, 2026
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Sep 7, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase III, randomized, double-blind, placebo-controlled study will compare the efficacy, safety, and pharmacokinetics of polatuzumab vedotin plus R-CHP versus R-CHOP in participants with previously untreated diffuse large B-cell lymphoma (DLBCL).
Conditions
- Diffuse Large B-Cell Lymphoma
Interventions
Polatuzumab VedotinDrug
Polatuzumab vedotin IV infusion will be administered as per the schedule specified in the respective arm.
RituximabDrug
Rituximab IV infusion will be administered as per the schedule specified in the respective arm.
CyclophosphamideDrug
Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.
DoxorubicinDrug
Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
VincristineDrug
Vincristine IV infusion will be administered as per the schedule specified in the respective arm.
Vincristine PlaceboDrug
Placebo matching to vincristine will be administered as per the schedule specified in the respective arm.
PrednisoneDrug
Prednisone PO will be administered as per the schedule specified in the respective arm.
Polatuzumab vedotin PlaceboDrug
Placebo matching to polatuzumab vedotin will be administered as per the schedule specified in the respective arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS) as Assessed by the Investigator, Using the Lugano Response Criteria for Malignant LymphomaTime frame: From randomization to the first occurrence of disease progression or relapse, or death from any cause, whichever occurs earlier (up to 38 months)
Locations
209 sites in 22 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Southern Cancer Center
Daphne, Alabama
City of Hope
Duarte, California
Ronald Reagan UCLA Medical Center
Los Angeles, California
Rocky Mountain Cancer Centers, LLP
Aurora, Colorado
Georgetown University Medical Center
Washington D.C., District of Columbia
Florida Cancer Specialists - Fort Myers (New Hampshire Ct)
Fort Myers, Florida
Florida Cancer Specialists & Research Institute
St. Petersburg, Florida
Florida Cancer Specialists & Research Institute
St. Petersburg, Florida
Emory University
Atlanta, Georgia
Illinois Cancer Specialists
Arlington Heights, Illinois
James Graham Brown Cancer Center
Louisville, Kentucky
Ochsner Medical Center
New Orleans, Louisiana
University of Maryland
Baltimore, Maryland
The Johns Hopkins Hospital
Baltimore, Maryland
Massachusetts General Hospital
Boston, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts
University of Michigan Health System
Ann Arbor, Michigan
Karmanos Cancer Center
Detroit, Michigan
Washington University
St Louis, Missouri
Roswell Park Cancer Institute
Buffalo, New York
Memorial Sloan Kettering Cancer Center at Westchester
Harrison, New York
New York University Cancer Cen
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Memorial Sloan Kettering Cancer Center - Commack
New York, New York
University of Rochester Medical Center
Rochester, New York
University of North Carolina School of Medicine
Chapel Hill, North Carolina
Levine Cancer Institute - Clincal Trials Administration
Charlotte, North Carolina
Oncology Hematology Care
Cincinnati, Ohio
The Ohio State University Comprehensive Cancer Center
Cleveland, Ohio
University Hospitals Case Medical Center
Cleveland, Ohio
Oncology Associates of Oregon, P.C
Eugene, Oregon
Northwest Cancer Specialists - Portland (SW Barnes Rd)
Portland, Oregon
Oregon Health & Science University
Portland, Oregon
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania
Fox Chase Cancer Center
Philadelphia, Pennsylvania
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania
Medical University of South Carolina (MUSC)
Charleston, South Carolina
Prisma Health ? Upstate
Greenville, South Carolina
Greco-Hainesworth Centers for Research
Chattanooga, Tennessee
Showing 40 of 209 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.